Jayant V. Rajan

Jayant V. Rajan

Auto-generated profile, based on publicly available information

Jayant V. Rajan

Department of Biochemistry and Biophysics, University of California San Francisco; San Francisco

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
JSJoseph J. Sabatino
Joseph J. Sabatino
KMKristen Mittl
Kristen Mittl
WRWilliam Rowles
William Rowles
KMKira Mcpolin
Kira Mcpolin
JRJayant V. Rajan
Jayant V. Rajan
RBRiley Bove
Riley Bove
Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.

24 January 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HKHannah M. Kortbawi
Hannah M. Kortbawi
RMRyan J. Marczak
Ryan J. Marczak
JRJayant V. Rajan
Jayant V. Rajan
NBNash L. Bulaong
Nash L. Bulaong
JPJohn Pak
John Pak
JWJeffrey D. Whitman
Jeffrey D. Whitman
Infection by Trypanosoma cruzi , the agent of Chagas disease, can irreparably damage the cardiac and gastrointestinal systems during decades of parasite persistence and related inflammation in these tissues. Diagnosis of chronic disease requires confirmation by multiple serological assays due to the imperfect performance of existing clinical tests. Current serology tests utilize antigens discovered over three decades ago with small specimen sets predominantly from South America, and lower test performance has been observed in patients who acquired T. cruzi infection in Central America and Mexico. Here, we attempt to address this gap by evaluating antibody responses against the entire T. cruzi proteome with phage display immunoprecipitation sequencing comprised of 228,127 47-amino acid peptides. We utilized diverse specimen sets from Mexico, Central America and South America, as well as different stages of cardiac disease severity, from 185 cases and 143 controls. We identified over 1,300 antigenic T. cruzi peptides derived from 961 proteins between specimen sets. A total of 67 peptides were reactive in 70% of samples across all regions, and 3 peptide epitopes were enriched in ≥90% of seropositive samples. Of these three, only one antigen, belonging to the trans-sialidase family, has not previously been described as a diagnostic target. Orthogonal validation of this peptide demonstrated increased antibody reactivity for infections originating from Central America. Overall, this study provides proteome-wide identification of seroreactive T. cruzi peptides across a large cohort spanning multiple endemic areas and identified a novel trans-sialidase peptide antigen (TS-2.23) with significant potential for translation into diagnostic serological assays. One Sentence Summary: Phage display immunoprecipitation sequencing (PhIP-seq) designed with a T. cruzi whole proteome library reveals a trans-sialidase peptide antigen (TS-2.23) with antibody responses highly prevalent across endemic regions of Latin America.